Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
64
NBIX Quote, Financials, Valuation and Earnings
Last price:
$145.16
Seasonality move
:
4.8%
Day range:
$144.65 - $146.79
52-week range:
$84.23 - $160.18
Dividend yield:
0%
P/E ratio:
34.69x
P/S ratio:
5.54x
P/B ratio:
4.82x
Volume:
693.8K
Avg. volume:
968.1K
1-year change:
4.48%
Market cap:
$14.5B
Revenue:
$2.4B
EPS (TTM):
$4.19
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NBIX
Neurocrine Biosciences, Inc.
|
$774M | $1.99 | 28.12% | 140.17% | $179.96 |
|
CV
Central Vermont Public Service Corp.
|
-- | -- | -- | -- | -- |
|
MASI
Masimo Corp.
|
$398.2M | $1.43 | -32.15% | 565.51% | $183.75 |
|
MRKR
Marker Therapeutics, Inc.
|
$600K | -$0.22 | -69.71% | -54.94% | $7.33 |
|
PFE
Pfizer Inc.
|
$14B | $0.76 | -4.58% | 694.41% | $28.62 |
|
PODD
Insulet Corp.
|
$714.4M | $1.19 | 28.59% | 5.4% | $377.72 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NBIX
Neurocrine Biosciences, Inc.
|
$145.26 | $179.96 | $14.5B | 34.69x | $0.00 | 0% | 5.54x |
|
CV
Central Vermont Public Service Corp.
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
MASI
Masimo Corp.
|
$132.76 | $183.75 | $7.1B | 116.80x | $0.00 | 0% | 4.20x |
|
MRKR
Marker Therapeutics, Inc.
|
$1.44 | $7.33 | $23.9M | -- | $0.00 | 0% | 3.89x |
|
PFE
Pfizer Inc.
|
$25.09 | $28.62 | $142.7B | 14.62x | $0.43 | 6.86% | 2.28x |
|
PODD
Insulet Corp.
|
$288.63 | $377.72 | $20.3B | 83.74x | $0.00 | 0% | 8.28x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NBIX
Neurocrine Biosciences, Inc.
|
13.77% | 1.498 | 3.43% | 2.89x |
|
CV
Central Vermont Public Service Corp.
|
-- | 0.000 | -- | -- |
|
MASI
Masimo Corp.
|
41.99% | 0.805 | 7.4% | 1.68x |
|
MRKR
Marker Therapeutics, Inc.
|
-- | 2.052 | -- | 5.66x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
|
PODD
Insulet Corp.
|
42.7% | 1.380 | 4.75% | 1.89x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NBIX
Neurocrine Biosciences, Inc.
|
$780.9M | $239.3M | 13.56% | 15.8% | 30.1% | $214.3M |
|
CV
Central Vermont Public Service Corp.
|
-- | -- | -- | -- | -- | -- |
|
MASI
Masimo Corp.
|
$230.6M | $83.7M | -11.41% | -19.18% | 22.53% | $49.7M |
|
MRKR
Marker Therapeutics, Inc.
|
-- | -$2.1M | -103.04% | -103.04% | -173.31% | -$2.7M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
|
PODD
Insulet Corp.
|
$513.5M | $117.7M | 9.14% | 18.92% | 16.66% | $94.6M |
Neurocrine Biosciences, Inc. vs. Competitors
-
Which has Higher Returns NBIX or CV?
Central Vermont Public Service Corp. has a net margin of 26.36% compared to Neurocrine Biosciences, Inc.'s net margin of --. Neurocrine Biosciences, Inc.'s return on equity of 15.8% beat Central Vermont Public Service Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NBIXNeurocrine Biosciences, Inc.98.24% $2.04 $3.5B CVCentral Vermont Public Service Corp.-- -- -- -
What do Analysts Say About NBIX or CV?
Neurocrine Biosciences, Inc. has a consensus price target of $179.96, signalling upside risk potential of 23.89%. On the other hand Central Vermont Public Service Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Neurocrine Biosciences, Inc. has higher upside potential than Central Vermont Public Service Corp., analysts believe Neurocrine Biosciences, Inc. is more attractive than Central Vermont Public Service Corp..
Company Buy Ratings Hold Ratings Sell Ratings NBIXNeurocrine Biosciences, Inc.19 3 0 CVCentral Vermont Public Service Corp.0 0 0 -
Is NBIX or CV More Risky?
Neurocrine Biosciences, Inc. has a beta of 0.273, which suggesting that the stock is 72.654% less volatile than S&P 500. In comparison Central Vermont Public Service Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NBIX or CV?
Neurocrine Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Central Vermont Public Service Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences, Inc. pays -- of its earnings as a dividend. Central Vermont Public Service Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBIX or CV?
Neurocrine Biosciences, Inc. quarterly revenues are $794.9M, which are larger than Central Vermont Public Service Corp. quarterly revenues of --. Neurocrine Biosciences, Inc.'s net income of $209.5M is higher than Central Vermont Public Service Corp.'s net income of --. Notably, Neurocrine Biosciences, Inc.'s price-to-earnings ratio is 34.69x while Central Vermont Public Service Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences, Inc. is 5.54x versus -- for Central Vermont Public Service Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBIXNeurocrine Biosciences, Inc.5.54x 34.69x $794.9M $209.5M CVCentral Vermont Public Service Corp.-- -- -- --
-
Which has Higher Returns NBIX or MASI?
Masimo Corp. has a net margin of 26.36% compared to Neurocrine Biosciences, Inc.'s net margin of 14.46%. Neurocrine Biosciences, Inc.'s return on equity of 15.8% beat Masimo Corp.'s return on equity of -19.18%.
Company Gross Margin Earnings Per Share Invested Capital NBIXNeurocrine Biosciences, Inc.98.24% $2.04 $3.5B MASIMasimo Corp.62.07% -$1.86 $1.4B -
What do Analysts Say About NBIX or MASI?
Neurocrine Biosciences, Inc. has a consensus price target of $179.96, signalling upside risk potential of 23.89%. On the other hand Masimo Corp. has an analysts' consensus of $183.75 which suggests that it could grow by 38.41%. Given that Masimo Corp. has higher upside potential than Neurocrine Biosciences, Inc., analysts believe Masimo Corp. is more attractive than Neurocrine Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBIXNeurocrine Biosciences, Inc.19 3 0 MASIMasimo Corp.4 3 0 -
Is NBIX or MASI More Risky?
Neurocrine Biosciences, Inc. has a beta of 0.273, which suggesting that the stock is 72.654% less volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.262, suggesting its more volatile than the S&P 500 by 26.208%.
-
Which is a Better Dividend Stock NBIX or MASI?
Neurocrine Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences, Inc. pays -- of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBIX or MASI?
Neurocrine Biosciences, Inc. quarterly revenues are $794.9M, which are larger than Masimo Corp. quarterly revenues of $371.5M. Neurocrine Biosciences, Inc.'s net income of $209.5M is higher than Masimo Corp.'s net income of $53.7M. Notably, Neurocrine Biosciences, Inc.'s price-to-earnings ratio is 34.69x while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences, Inc. is 5.54x versus 4.20x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBIXNeurocrine Biosciences, Inc.5.54x 34.69x $794.9M $209.5M MASIMasimo Corp.4.20x 116.80x $371.5M $53.7M
-
Which has Higher Returns NBIX or MRKR?
Marker Therapeutics, Inc. has a net margin of 26.36% compared to Neurocrine Biosciences, Inc.'s net margin of -162.11%. Neurocrine Biosciences, Inc.'s return on equity of 15.8% beat Marker Therapeutics, Inc.'s return on equity of -103.04%.
Company Gross Margin Earnings Per Share Invested Capital NBIXNeurocrine Biosciences, Inc.98.24% $2.04 $3.5B MRKRMarker Therapeutics, Inc.-- -$0.12 $18.4M -
What do Analysts Say About NBIX or MRKR?
Neurocrine Biosciences, Inc. has a consensus price target of $179.96, signalling upside risk potential of 23.89%. On the other hand Marker Therapeutics, Inc. has an analysts' consensus of $7.33 which suggests that it could grow by 411.03%. Given that Marker Therapeutics, Inc. has higher upside potential than Neurocrine Biosciences, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than Neurocrine Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBIXNeurocrine Biosciences, Inc.19 3 0 MRKRMarker Therapeutics, Inc.3 0 0 -
Is NBIX or MRKR More Risky?
Neurocrine Biosciences, Inc. has a beta of 0.273, which suggesting that the stock is 72.654% less volatile than S&P 500. In comparison Marker Therapeutics, Inc. has a beta of 1.350, suggesting its more volatile than the S&P 500 by 34.977%.
-
Which is a Better Dividend Stock NBIX or MRKR?
Neurocrine Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marker Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences, Inc. pays -- of its earnings as a dividend. Marker Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBIX or MRKR?
Neurocrine Biosciences, Inc. quarterly revenues are $794.9M, which are larger than Marker Therapeutics, Inc. quarterly revenues of $1.2M. Neurocrine Biosciences, Inc.'s net income of $209.5M is higher than Marker Therapeutics, Inc.'s net income of -$2M. Notably, Neurocrine Biosciences, Inc.'s price-to-earnings ratio is 34.69x while Marker Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences, Inc. is 5.54x versus 3.89x for Marker Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBIXNeurocrine Biosciences, Inc.5.54x 34.69x $794.9M $209.5M MRKRMarker Therapeutics, Inc.3.89x -- $1.2M -$2M
-
Which has Higher Returns NBIX or PFE?
Pfizer Inc. has a net margin of 26.36% compared to Neurocrine Biosciences, Inc.'s net margin of 21.32%. Neurocrine Biosciences, Inc.'s return on equity of 15.8% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital NBIXNeurocrine Biosciences, Inc.98.24% $2.04 $3.5B PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About NBIX or PFE?
Neurocrine Biosciences, Inc. has a consensus price target of $179.96, signalling upside risk potential of 23.89%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.08%. Given that Neurocrine Biosciences, Inc. has higher upside potential than Pfizer Inc., analysts believe Neurocrine Biosciences, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBIXNeurocrine Biosciences, Inc.19 3 0 PFEPfizer Inc.7 15 1 -
Is NBIX or PFE More Risky?
Neurocrine Biosciences, Inc. has a beta of 0.273, which suggesting that the stock is 72.654% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock NBIX or PFE?
Neurocrine Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.86% to investors and pays a quarterly dividend of $0.43 per share. Neurocrine Biosciences, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios NBIX or PFE?
Neurocrine Biosciences, Inc. quarterly revenues are $794.9M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Neurocrine Biosciences, Inc.'s net income of $209.5M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Neurocrine Biosciences, Inc.'s price-to-earnings ratio is 34.69x while Pfizer Inc.'s PE ratio is 14.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences, Inc. is 5.54x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBIXNeurocrine Biosciences, Inc.5.54x 34.69x $794.9M $209.5M PFEPfizer Inc.2.28x 14.62x $16.7B $3.6B
-
Which has Higher Returns NBIX or PODD?
Insulet Corp. has a net margin of 26.36% compared to Neurocrine Biosciences, Inc.'s net margin of 12.4%. Neurocrine Biosciences, Inc.'s return on equity of 15.8% beat Insulet Corp.'s return on equity of 18.92%.
Company Gross Margin Earnings Per Share Invested Capital NBIXNeurocrine Biosciences, Inc.98.24% $2.04 $3.5B PODDInsulet Corp.72.7% $1.24 $2.4B -
What do Analysts Say About NBIX or PODD?
Neurocrine Biosciences, Inc. has a consensus price target of $179.96, signalling upside risk potential of 23.89%. On the other hand Insulet Corp. has an analysts' consensus of $377.72 which suggests that it could grow by 30.87%. Given that Insulet Corp. has higher upside potential than Neurocrine Biosciences, Inc., analysts believe Insulet Corp. is more attractive than Neurocrine Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBIXNeurocrine Biosciences, Inc.19 3 0 PODDInsulet Corp.19 2 0 -
Is NBIX or PODD More Risky?
Neurocrine Biosciences, Inc. has a beta of 0.273, which suggesting that the stock is 72.654% less volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.374, suggesting its more volatile than the S&P 500 by 37.428%.
-
Which is a Better Dividend Stock NBIX or PODD?
Neurocrine Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences, Inc. pays -- of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBIX or PODD?
Neurocrine Biosciences, Inc. quarterly revenues are $794.9M, which are larger than Insulet Corp. quarterly revenues of $706.3M. Neurocrine Biosciences, Inc.'s net income of $209.5M is higher than Insulet Corp.'s net income of $87.6M. Notably, Neurocrine Biosciences, Inc.'s price-to-earnings ratio is 34.69x while Insulet Corp.'s PE ratio is 83.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences, Inc. is 5.54x versus 8.28x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBIXNeurocrine Biosciences, Inc.5.54x 34.69x $794.9M $209.5M PODDInsulet Corp.8.28x 83.74x $706.3M $87.6M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
